Role of taraxerone isolated from Leucas lavandulifolia, as an immunomodulator

Jayaraman, Sony; Variyar, E. Jayadevi

doi:10.1016/j.jep.2021.114307

Cited by 11 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 43 On the other hand, peak 10 (14.9%), attributed to taraxerone , a pentacyclo-triterpenoid, is widely reported for its immune-modulating effect, as well as antifungal and antiviral activities. 44 In addition, other components found are important chemical platforms, such as 5-HMF (peak 3), widely used in the production of inks, dyes, personal care products, rubber, and plastic, among others. 45 The main compounds were grouped according to their main functional groups.…”

Section: Resultsmentioning

confidence: 99%

Upcycling agro-industrial blueberry waste into platform chemicals and structured materials for application in marine environments

et al. 2022

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Upcycling agro-industrial blueberry waste into platform chemicals and structured materials for application in marine environments

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Taraxerone, an active constituent of the traditional Chinese herb threadleaf white velvet , is a compound derived from its herbal extract. Notably, taraxerone has been shown to exhibit remarkable immunomodulatory, antiallergic, anti‐inflammatory, hypoglycemic, and other notable biological effects (Ahmed et al, 2010; Barboza et al, 2020; Chunhakant & Chaicharoenpong, 2019; Jayaraman & Variyar, 2021; Mawa et al, 2016; Monteiro et al, 2022; Sung et al, 2012). However, the effects and mechanisms of action of taraxerone on pulmonary fibrosis remain unclear.…”

Section: Introductionmentioning

confidence: 99%

Taraxerone exerts antipulmonary fibrosis effect through Smad signaling pathway and antioxidant stress response in a Sirtuin1‐dependent manner

Chen,

Xie,

Tang

et al. 2024

Phytotherapy Research

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis treatments are limited, often with severe side effects, highlighting the need for novel options. Taraxerone has diverse biomedical properties, but its mechanism remains unclear. This study investigates taraxerone's impact and the mechanisms involved in bleomycin‐induced pulmonary fibrosis in mice. After establishing a pulmonary fibrosis mouse model, taraxerone was intraperitoneally injected continuously for 14–28 days. The in vivo antifibrotic and antioxidative stress effects of taraxerone were assessed. In vitro, the influence of taraxerone on transforming growth factor‐β1‐induced myofibroblast transformation and oxidative stress was investigated. Subsequently, quantitative polymerase chain reaction screened the histone deacetylase and Sirtuin family, and taraxerone's effects on SIRT1 were assessed. After SIRT1 siRNA treatment, changes in myofibroblast transformation and antioxidant capacity in response to taraxerone were observed. Acetylation and phosphorylation levels of Smad3 were evaluated. We also examined the binding levels of SIRT1 with Pho‐Smad3 and Smad3, as well as the nuclear localization of Smad2/3. EX527 confirmed SIRT1's in vivo action in response to taraxerone. In vitro experiments suggested that taraxerone inhibited myofibroblast differentiation by activating SIRT1 and reducing oxidative stress. We also observed a new interaction between SIRT1 and the Smad complex. Taraxerone activates SIRT1, enabling it to bind directly to Smad3. This leads to reduced Smad complex phosphorylation and limited nuclear translocation. As a result, the transcription of fibrotic factors is reduced. In vivo validation confirms taraxerone's SIRT1‐mediated antifibrotic effectiveness. This suggests that targeting SIRT1‐mediated inhibition of myofibroblast differentiation could be a key strategy in taraxerone‐based therapy for pulmonary fibrosis.

show abstract